Product Description
CT-P59 was identified as a potential treatment for COVID-19 through screening of antibody candidates and selecting those that showed the highest potency in neutralising the SARS-CoV-2 virus.
Mechanisms of Action: RBD Binder
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Belgium | Croatia | Czech | Estonia | European Medicines Agency | Finland | Germany | Hungary | Iceland | Indonesia | Ireland | Italy | Korea | Latvia | Lithuania | Netherlands | Peru | Poland | Portugal | Romania | Slovakia | Spain | Sweden | Switzerland | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Celltrion
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Coronavirus Infections
Phase 3: Coronavirus Infections|Severe Acute Respiratory Syndrome|Communicable Diseases|COVID-19
Phase 1: COVID-19
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT05982704 | P4 |
Active, not recruiting |
Coronavirus Infections |
2022-09-19 |
|
| 2020-003369-20 | P3 |
Completed |
Severe Acute Respiratory Syndrome|COVID-19 |
2022-05-13 |
|
| 2020-003401-60 | P3 |
Completed |
Coronavirus Infections|Severe Acute Respiratory Syndrome |
2022-03-23 |
|
| CT-P59 3.2 | P3 |
Completed |
COVID-19|Communicable Diseases |
2021-05-21 |